Scarica l'app Stockscreener
21.54
3.75%
-0.84
Precedente Chiudi:
$22.38
Aprire:
$22.29
Volume 24 ore:
51,837
Relative Volume:
0.53
Capitalizzazione di mercato:
$235.76M
Reddito:
$56.54M
Utile/perdita netta:
$-30.70M
Rapporto P/E:
-55.23
EPS:
-0.39
Flusso di cassa netto:
$-31.05M
1 W Prestazione:
-10.03%
1M Prestazione:
-2.89%
6M Prestazione:
+65.69%
1 anno Prestazione:
+56.09%
Intervallo 1D:
$21.23
$22.30
Intervallo di 1 settimana:
$20.50
$24.95
Portata 52W:
$10.00
$28.42
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Nome
Cidara Therapeutics Inc
Settore
Industria
Telefono
858-752-6170
Indirizzo
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Confronta CDTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
21.54 | 235.76M | 56.54M | -30.70M | -31.05M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-27 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-12-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-08 | Iniziato | Guggenheim | Buy |
| 2024-08-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | Ripresa | H.C. Wainwright | Buy |
| 2021-09-22 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | Iniziato | Aegis Capital | Buy |
| 2019-09-04 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-07-26 | Iniziato | Citigroup | Buy |
| 2017-04-21 | Iniziato | Raymond James | Strong Buy |
| 2017-04-17 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-04-11 | Ripresa | Wedbush | Outperform |
| 2017-02-22 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-22 | Aggiornamento | WBB Securities | Sell → Hold |
| 2016-12-21 | Ripresa | Leerink Partners | Outperform |
| 2016-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2016-09-23 | Downgrade | WBB Securities | Hold → Sell |
| 2015-10-09 | Aggiornamento | WBB Securities | Sell → Hold |
| 2015-05-11 | Iniziato | Jefferies | Buy |
| 2015-05-11 | Iniziato | Leerink Partners | Outperform |
| 2015-05-11 | Iniziato | Needham | Buy |
| 2015-05-11 | Iniziato | Wedbush | Outperform |
| 2015-04-23 | Iniziato | WBB Securities | Sell |
Mostra tutto
Cidara Therapeutics Inc Borsa (CDTX) Ultime notizie
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Increase in Short Interest - MarketBeat
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Bourla becomes chair of PhRMA - BioCentury
Invasive Candidiasis Market to Reach New Heights in Growth - openPR
Brokerages Set Cidara Therapeutics, Inc. (NASDAQ:CDTX) Price Target at $32.20 - Defense World
Cidara Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective February 24, 2025 - Marketscreener.com
Cidara CFO steps down, new appointment announced By Investing.com - Investing.com South Africa
Cidara Therapeutics Announces Appointment Of Frank Karbe As Chief Financial Officer - Marketscreener.com
Cidara Therapeutics Announces CFO Transition - TipRanks
Cidara CFO steps down, new appointment announced - Investing.com
Cidara Therapeutics appoints new CFO amid flu drug trials - Investing.com India
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer - GlobeNewswire
Strategic CFO Hire: $4B Deal Architect Frank Karbe Joins Cidara as Growth Plans Accelerate - StockTitan
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Crosses Above Fifty Day Moving AverageHere's What Happened - MarketBeat
Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention - Seeking Alpha
(CDTX) Trading Signals - Stock Traders Daily
Cidara Therapeutics (NASDAQ:CDTX) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Short Interest Up 113.6% in January - MarketBeat
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Inside Cidara's Next Move: CEO Jeffrey Stein Takes Center Stage at Elite Biotech Conference - StockTitan
Long Term Trading Analysis for (CDTX) - Stock Traders Daily
Cantor Fitzgerald raises Cidara stock to Overweight - MSN
Cidara Therapeutics’ (CDTX) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Cantor Fitzgerald raises Cidara stock to Overweight By Investing.com - Investing.com Canada
Cidara Therapeutics (NASDAQ:CDTX) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $32.20 Consensus Price Target from Analysts - MarketBeat
Contrasting Cidara Therapeutics (NASDAQ:CDTX) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Here’s Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing - MSN
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Short Interest Update - MarketBeat
Why These 24 Stocks Are Skyrocketing - Insider Monkey
Geode Capital Management LLC Buys 9,771 Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX) - Defense World
(CDTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Cidara Therapeutics (NASDAQ:CDTX) Shares Cross Above 50 Day Moving AverageTime to Sell? - MarketBeat
Cidara Therapeutics announces board changes, CMO separation - Investing.com
Cidara Therapeutics Announces Leadership Changes and Appointments - MSN
Cidara Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Cidara Therapeutics Inc Azioni (CDTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cidara Therapeutics Inc Azioni (CDTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Sep 11 '24 |
Sale |
11.64 |
909 |
10,580 |
17,788 |
| Stein Jeffrey | President & CEO |
Jun 07 '24 |
Buy |
13.21 |
8,000 |
105,680 |
24,580 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '24 |
Sale |
0.67 |
21,029 |
14,085 |
258,681 |
| Sandison Taylor | Chief Medical Officer |
Mar 11 '24 |
Sale |
0.67 |
20,662 |
13,839 |
347,095 |
| Ward Shane | COO & CLO |
Mar 11 '24 |
Sale |
0.67 |
20,473 |
13,713 |
198,770 |
| Shah Preetam | CFO & CBO |
Mar 11 '24 |
Sale |
0.67 |
18,931 |
12,680 |
227,210 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):